Haemonetics (HAE) Expected to Announce Earnings on Thursday

Haemonetics (NYSE:HAE) is anticipated to release its earnings data before the market opens on Thursday, February 13th. Analysts expect Haemonetics to post earnings of $1.20 per share and revenue of $354.46 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. During the same period last year, the firm earned $0.99 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Trading Up 3.4 %

Shares of HAE stock opened at $71.26 on Thursday. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The company has a market cap of $3.58 billion, a price-to-earnings ratio of 29.57, a PEG ratio of 1.07 and a beta of 0.39. Haemonetics has a 1 year low of $65.73 and a 1 year high of $97.97. The firm has a fifty day moving average price of $77.77 and a 200-day moving average price of $78.79.

Analysts Set New Price Targets

Several analysts have issued reports on HAE shares. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a report on Friday, November 8th. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $112.00 target price on shares of Haemonetics in a research note on Tuesday, December 3rd. Finally, Barrington Research reiterated an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a research report on Wednesday, December 4th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $108.78.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.